Bladder Cancer

Findings from a retrospective analysis highlight no significant differences in metastasis-free survival in patients with muscle-invasive bladder cancer who received radical cystectomy vs trimodality therapy.

The FDA requests additional data and a safety update regarding N-803 plus BCG as a treatment for patients with BCG-unresponsive non-muscle invasive bladder carcinoma.

An artificial intelligence-based model for detecting lymph node metastases appears to identify tumor micrometastases in bladder cancer that pathologists may miss while classifying patient results as negative.

Data from the phase 2 TITAN-TCC trial suggest that early non-responders with metastatic urothelial carcinoma with PD-L1–positive tumors benefit from nivolumab plus nivolumab/ipilimumab boosts.

Nazy Zomorodian, NP, spoke with CancerNetwork® about the unique dosing schedule of enfortumab vedotin plus pembrolizumab following its accelerated approval by the FDA in advanced/metastatic urothelial cancer.

Results from cohort K of the phase 1b/2 KEYNOTE-869 trial led to the accelerated approval of enfortumab vedotin plus pembrolizumab in patients with locally advanced or metastatic urothelial cancer who cannot receive cisplatin-based chemotherapy.

Shilpa Gupta, MD, discusses bladder preserving strategies for unfit or young patients, trials assessing immunotherapy combinations, and results from the BLASST-1 trial presented at ASCO GU.

Shilpa Gupta, MD, shares the current standard of care for muscle-invasive bladder cancer and highlights other options that may be suitable for some patients.

An expert from Chase Comprehensive Cancer Center discusses how findings from a genomic analysis of the phase 2 BLASST-1 trial may identify biomarkers of response and resistance to nivolumab/chemotherapy in muscle-invasive bladder cancer.

A retrospective study clarifies how the implementation of avelumab maintenance looks in real-world practice, according to an expert from Seattle Cancer Care Alliance.

First-line maintenance with avelumab in locally advanced or metastatic urothelial carcinoma yields efficacy that appears consistent between clinical and real-world settings.

Results from the phase 3 IMvigor130 trial reveal a trend towards overall survival improvement when atezolizumab plus chemotherapy was given to patients with locally advanced or metastatic urothelial carcinoma vs placebo.

An exploratory analysis indicates that overall survival did not improve with the use of single-agent atezolizumab in untreated locally advanced or metastatic urothelial cancer.

Pembrolizumab appears to achieve antitumor activity in terms of disease-free survival in patients with Bacillus calmette-guerin–unresponsive, papillary high–risk, non-muscle invasive bladder cancer.

Extended follow-up findings further support the use of nivolumab as a standard of care in high-risk muscle-invasive urothelial carcinoma following radical resection.

Data from the phase 2 TROPHY-U-01 trial support further evaluation of sacituzumab govitecan in patients with metastatic urothelial cancer following immune checkpoint inhibitor therapy, according to the lead investigator.

Findings from the phase 2 UNITE study indicate that certain biomarkers may help inform clinical decision making and sequencing in patients with advanced urothelial carcinoma.

Almost half of patients with muscle-invasive bladder cancer in a phase 2 trial had clinical complete responses following transurethral resection of bladder tumors plus nivolumab and chemotherapy.

Investigators identify an association between circulating tumor DNA in the blood plasma detected via the RaDaR assay and response to treatment with neoadjuvant immunotherapy for muscle-invasive bladder cancer.

Patients with previously untreated, locally advanced or metastatic urothelial carcinoma responded to treatment with trilaciclib and avelumab.

BT8009 monotherapy, which received fast track designation from the FDA, may be beneficial for adult patients with locally advanced or metastatic urothelial cancer.

The FDA has set the Prescription Drug User Fee Act date for April 21, 2023 for each supplemental biologics license application of enfortumab vedotin-ejfv and pembrolizumab in urothelial carcinoma.

Patients with high-risk Bacillus Calmette Guérin–unresponsive non-muscle invasive bladder cancer can now receive treatment with nadofaragene firadenovec-vncg—the first gene therapy—following its approval by the FDA.

Long-term follow-up showed that the use of pembrolizumab monotherapy maintained durable complete responses, while rates of upstaging at the time of radical cystectomy were consistent with previous findings in the KEYNOTE-057 trial in patients with a bladder cancer subset.

Findings from an interim analysis of data show that the addition of blue light cystoscopy to conventional white light significantly improved clinical outcomes in a group of patients with non–muscle-invasive bladder cancer.

Patients with cisplatin-ineligible muscle-invasive bladder cancer experienced a better rate of downstaging and improved survival benefit with neoadjuvant pembrolizumab prior to radical cystectomy vs immediate radical cystectomy.

With the increasing clinical use of circulating tumor DNA biomarker testing among community urologists, an expert from Tisch Cancer Institute at Mount Sinai in New York City suggests that more prospective data are needed to make the best decisions among patients with bladder cancer.

Atezolizumab is no longer available to treat patients with advanced or metastatic bladder cancer following the manufacturer’s decision to withdraw its U.S. indication after consulting with the FDA.

Rogaratinib showed similar efficacy and manageable safety compared with chemotherapy in the management of FGFR1/3 mRNA–positive locally advanced or metastatic urothelial carcinoma.

A brief review of both neoadjuvant and adjuvant treatment options available to patients with localized bladder cancer.